DFMO approved for use in Australia

We’re thrilled to announce that Norgine has received regulatory approval from the Therapeutics Goods Administration (TGA) to distribute DFMO, a life-changing treatment for neuroblastoma, in Australia. We are the first country outside of the U.S to receive such approval.